No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer

Ellen L Goode, Csilla Szabo, Ludmila Prokunina-Olsson, Robert A. Vierkant, Zachary S. Fredericksen, Francis S. Collins, Kristin L. White, Michele Schmidt, Brooke L. Fridley, Fergus J Couch

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: TCF7L2 is a transcription factor involved in Wnt/β-catenin signaling which has a variant known to be associated with risk of Type 2 diabetes and, in some studies, with risk of certain cancers, including familial breast cancer. No studies of ovarian cancer have been reported to date. Methods: Two clinic-based case-control studies at the Mayo Clinic were assessed including 798 breast cancer cases, 843 breast cancer controls, 391 ovarian cancer cases, and 458 ovarian cancer controls. Genotyping at TCF7L2 rs12255372 used a 5' endonuclease assay, and statistical analysis used logistic regression among participants as a whole and among a priori-defined subsets. Results: No associations with risk of breast or ovarian cancer were observed (ordinal model, p = 0.62 and p = 0.75, respectively). In addition, no associations were observed among sub-groups defined by age, BMI, family history, stage, grade, histology, or tumor behavior. Conclusion: Although the biology of the Wnt/β-catenin signaling pathway and prior association between rs12255372 and numerous phenotypes warranted examination of this TCF7L2 SNP, no compelling evidence for association with breast or ovarian cancer was observed.

Original languageEnglish (US)
Article number1471
Pages (from-to)312
Number of pages1
JournalBMC Cancer
Volume9
DOIs
StatePublished - Sep 4 2009

Fingerprint

Ovarian Neoplasms
Breast Neoplasms
Catenins
Wnt Signaling Pathway
Endonucleases
Type 2 Diabetes Mellitus
Single Nucleotide Polymorphism
Case-Control Studies
Neoplasms
Histology
Transcription Factors
Age Groups
Logistic Models
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Goode, E. L., Szabo, C., Prokunina-Olsson, L., Vierkant, R. A., Fredericksen, Z. S., Collins, F. S., ... Couch, F. J. (2009). No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. BMC Cancer, 9, 312. [1471]. https://doi.org/10.1186/1471-2407-9-312

No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. / Goode, Ellen L; Szabo, Csilla; Prokunina-Olsson, Ludmila; Vierkant, Robert A.; Fredericksen, Zachary S.; Collins, Francis S.; White, Kristin L.; Schmidt, Michele; Fridley, Brooke L.; Couch, Fergus J.

In: BMC Cancer, Vol. 9, 1471, 04.09.2009, p. 312.

Research output: Contribution to journalArticle

Goode, EL, Szabo, C, Prokunina-Olsson, L, Vierkant, RA, Fredericksen, ZS, Collins, FS, White, KL, Schmidt, M, Fridley, BL & Couch, FJ 2009, 'No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer', BMC Cancer, vol. 9, 1471, pp. 312. https://doi.org/10.1186/1471-2407-9-312
Goode EL, Szabo C, Prokunina-Olsson L, Vierkant RA, Fredericksen ZS, Collins FS et al. No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. BMC Cancer. 2009 Sep 4;9:312. 1471. https://doi.org/10.1186/1471-2407-9-312
Goode, Ellen L ; Szabo, Csilla ; Prokunina-Olsson, Ludmila ; Vierkant, Robert A. ; Fredericksen, Zachary S. ; Collins, Francis S. ; White, Kristin L. ; Schmidt, Michele ; Fridley, Brooke L. ; Couch, Fergus J. / No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. In: BMC Cancer. 2009 ; Vol. 9. pp. 312.
@article{c001850a626342fb9ba5a10943a228a4,
title = "No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer",
abstract = "Background: TCF7L2 is a transcription factor involved in Wnt/β-catenin signaling which has a variant known to be associated with risk of Type 2 diabetes and, in some studies, with risk of certain cancers, including familial breast cancer. No studies of ovarian cancer have been reported to date. Methods: Two clinic-based case-control studies at the Mayo Clinic were assessed including 798 breast cancer cases, 843 breast cancer controls, 391 ovarian cancer cases, and 458 ovarian cancer controls. Genotyping at TCF7L2 rs12255372 used a 5' endonuclease assay, and statistical analysis used logistic regression among participants as a whole and among a priori-defined subsets. Results: No associations with risk of breast or ovarian cancer were observed (ordinal model, p = 0.62 and p = 0.75, respectively). In addition, no associations were observed among sub-groups defined by age, BMI, family history, stage, grade, histology, or tumor behavior. Conclusion: Although the biology of the Wnt/β-catenin signaling pathway and prior association between rs12255372 and numerous phenotypes warranted examination of this TCF7L2 SNP, no compelling evidence for association with breast or ovarian cancer was observed.",
author = "Goode, {Ellen L} and Csilla Szabo and Ludmila Prokunina-Olsson and Vierkant, {Robert A.} and Fredericksen, {Zachary S.} and Collins, {Francis S.} and White, {Kristin L.} and Michele Schmidt and Fridley, {Brooke L.} and Couch, {Fergus J}",
year = "2009",
month = "9",
day = "4",
doi = "10.1186/1471-2407-9-312",
language = "English (US)",
volume = "9",
pages = "312",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer

AU - Goode, Ellen L

AU - Szabo, Csilla

AU - Prokunina-Olsson, Ludmila

AU - Vierkant, Robert A.

AU - Fredericksen, Zachary S.

AU - Collins, Francis S.

AU - White, Kristin L.

AU - Schmidt, Michele

AU - Fridley, Brooke L.

AU - Couch, Fergus J

PY - 2009/9/4

Y1 - 2009/9/4

N2 - Background: TCF7L2 is a transcription factor involved in Wnt/β-catenin signaling which has a variant known to be associated with risk of Type 2 diabetes and, in some studies, with risk of certain cancers, including familial breast cancer. No studies of ovarian cancer have been reported to date. Methods: Two clinic-based case-control studies at the Mayo Clinic were assessed including 798 breast cancer cases, 843 breast cancer controls, 391 ovarian cancer cases, and 458 ovarian cancer controls. Genotyping at TCF7L2 rs12255372 used a 5' endonuclease assay, and statistical analysis used logistic regression among participants as a whole and among a priori-defined subsets. Results: No associations with risk of breast or ovarian cancer were observed (ordinal model, p = 0.62 and p = 0.75, respectively). In addition, no associations were observed among sub-groups defined by age, BMI, family history, stage, grade, histology, or tumor behavior. Conclusion: Although the biology of the Wnt/β-catenin signaling pathway and prior association between rs12255372 and numerous phenotypes warranted examination of this TCF7L2 SNP, no compelling evidence for association with breast or ovarian cancer was observed.

AB - Background: TCF7L2 is a transcription factor involved in Wnt/β-catenin signaling which has a variant known to be associated with risk of Type 2 diabetes and, in some studies, with risk of certain cancers, including familial breast cancer. No studies of ovarian cancer have been reported to date. Methods: Two clinic-based case-control studies at the Mayo Clinic were assessed including 798 breast cancer cases, 843 breast cancer controls, 391 ovarian cancer cases, and 458 ovarian cancer controls. Genotyping at TCF7L2 rs12255372 used a 5' endonuclease assay, and statistical analysis used logistic regression among participants as a whole and among a priori-defined subsets. Results: No associations with risk of breast or ovarian cancer were observed (ordinal model, p = 0.62 and p = 0.75, respectively). In addition, no associations were observed among sub-groups defined by age, BMI, family history, stage, grade, histology, or tumor behavior. Conclusion: Although the biology of the Wnt/β-catenin signaling pathway and prior association between rs12255372 and numerous phenotypes warranted examination of this TCF7L2 SNP, no compelling evidence for association with breast or ovarian cancer was observed.

UR - http://www.scopus.com/inward/record.url?scp=70349850357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349850357&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-9-312

DO - 10.1186/1471-2407-9-312

M3 - Article

C2 - 19732438

AN - SCOPUS:70349850357

VL - 9

SP - 312

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 1471

ER -